2024-03-14T13:25:14-05:00 2023-12-31 464553740 MANN & ASSOCIATES APC 2535 TRUXTUN ROAD STE 207 SAN DIEGO CA 92106 990 2023-01-01 452210161 THE BIOMEDICAL RESEARCH INSTITUTE OF SOUTHERN CALIFORNIA BIOM 8887235830 4225-H OCEANSIDE BLVD 273 OCEANSIDE CA 92056 SALLY SARAWAR PRESIDENT 8887235830 2024-03-07 1 SALLY SARAWAR 999009999 0 JEANNE M MANN CPA P00229468 6192225900 2 AAL1 IAL1 2023 2023-04-26 12:10:37Z SALLY SARAWAR 4225-H OCEANSIDE BLVD 273 OCEANSIDE CA 92056 308369 0 X HTTP://BRI-SC.ORG/ X 2011 CA TO CONDUCT BASIC AND TRANSLATIONAL BIOMEDICAL RESEARCH AIMED AT UNDERSTANDING, PREVENTING OR CURING HUMAN DISEASE. 4 3 3 0 0 0 2886 178181 0 0 0 0 69542 30068 72428 208249 0 0 0 0 3249 101118 0 0 0 87780 87877 91029 188995 -18601 19254 36696 60330 51096 55476 -14400 4854 X THE MISSION OF THIS ORGANIZATION IS TO CONDUCT SCIENTIFIC RESEARCH AIMED AT CURING OR PREVENTING HUMAN DISEASE. WE WILL CONDUCT BASIC RESEARCH AIMED AT UNDERSTANDING THE FUNDAMENTAL MECHANISMS OF NORMAL BIOLOGICAL PROCESSES AND HOW THESE DIFFER IN DISEASE STATES. THIS WILL HELP US TO IDENTIFY NEW WAYS TO DIAGNOSE, PREVENT OR TREAT HUMAN DISEASE. WE WILL ALSO CONDUCT PRECLINICAL DISCOVERY RESEARCH INTO DEVELOPING AND TESTING NOVEL VACCINES AND THERAPEUTIC AGENTS FOR HUMAN DISEASE. 0 0 VIRAL IMMUNOLOGYTHE OBJECTIVE OF THIS PROGRAM IS TO CONDUCT RESEARCH INTO THE MECHANISMS BY WHICH THE IMMUNE SYSTEM PROTECTS AGAINST VIRAL INFECTIONS. THIS RESEARCH WILL HELP US TO DEVELOP BETTER VACCINES AND THERAPEUTIC AGENTS FOR VIRAL INFECTIONS. THIS PROGRAM INCLUDES PRE-CLINICAL WORK ON A NOVEL UNIVERSAL INFLUENZA VACCINE, THE MECHANISM BY WHICH IT PROTECTS AGAINST MULTIPLE STRAINS OF INFLUENZA AND WHETHER THE VACCINE PROTECTS AGAINST SECONDARY BACTERIAL INFECTIONS OFTEN INCREASE MORTALITY FROM INFLUENZA. WE ARE ALSO INVESTIGATING NOVEL VACCINE ADJUVANTS AND WHY IMMUNE RESPONSES TO CERTAIN VACCINES WANE OVER TIME. 171971 178181 DIABETESTHE GOAL OF THIS PROGRAM IS TO IDENTIFY UNIQUE EVENTS AND MOLECULAR PATHWAYS THAT CAN TRIGGER THE AUTOREACTIVE T CELLS TO CAUSE DESTRUCTION OF THE PANCREATIC ISLETS IN TYPE 1 DIABETES. THE ROLE OF EXOSOMES AND NOVEL SELF-ANTIGENS ENCODED BY ENDOGENOUS RETROVIRUSES IS A MAJOR FOCUS OF THIS STUDY. THE BLOOD BRAIN BARRIERTHE BLOOD-BRAIN BARRIER (BBB) PREVENTS BLOODBORNE SUBSTANCES FROM NON-SELECTIVELY CROSSING INTO THE BRAIN AND PLAYS A CRUCIAL ROLE IN PROTECTING THE BRAIN FROM HARMFUL SUBSTANCES AND PATHOGENS. HOWEVER, THE BBB ALSO SIGNIFICANTLY IMPEDES THE DELIVERY OF THERAPEUTIC AGENTS INTO THE BRAIN WHICH PRESENTS A MAJOR CHALLENGE FOR THE TARGETING AND DELIVERY OF PHARMACOLOGICAL AGENTS FOR THE TREATMENT OF VARIOUS CENTRAL NERVOUS SYSTEM (CNS) DISEASES, INCLUDING CANCERS, HIV INFECTION AND ALZHEIMER'S DISEASE. BRISC SCIENTISTS ARE STUDYING THE ROLE OF THE BBB IN HEALTH AND DISEASE AND ARE CONDUCTING COLLABORATIVE STUDIES ON NOVEL METHODS OF REVERSIBLY PERMEABILIZING THE BBB TO ALLOW ENTRY OF THERAPEUTIC AGENTS. 171971 1 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 3 1 0 0 0 0 0 0 0 0 0 0 X 4 3 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 CA X PETER DIAS 8887235830 4225-H OCEANSIDE BLVD 273 OCEANSIDE CA 92056 DR CRAIG JACKSON CHAIRMAN OF BOARD OF DIREC 0.50 X 0 0 0 DR LEMAN YEL DIRECTOR 0.30 X 0 0 0 DR PETER DIAS CFO 20.00 X X 0 0 0 MR MICHAEL GISKE DIRECTOR 0.50 X 0 0 0 DR SALLY SARAWAR PRESIDENT AND CEO 20.00 X 34683 0 0 34683 0 0 0 0 0 0 0 178181 178181 130188 100120 30068 30068 30068 208249 0 0 30068 7272 7272 86767 86767 7079 7079 1450 1450 2526 200 2326 1235 301 934 8454 5461 2993 335 335 2990 1057 1933 LABORATORY SUPPLIES & S 70522 70506 16 EQUIPMENT RENTAL, REPAI 286 191 95 OTHER 79 74 5 188995 171971 17024 0 34928 60381 1768 -51 36696 60330 7528 7528 485 485 30000 30000 13083 17463 51096 55476 X -14400 4854 -14400 4854 36696 60330 19254 0 X 0 0 0 X 924036 352753 138085 2886 178181 1595941 924036 352753 138085 2886 178181 1595941 1595941 69542 130188 199730 1795671 0.88880 0.96980 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 SECURITY DEPOSIT 4519 CREDIT CARD 2914 PAYROLL LIABILITIES -470 ACCRUED LIABILITIES 10500 17463 SALLY SARAWAR OFFICER TO PROVIDE A FINANCIAL BUFFER FOR ORGANIZATION TO PREVENT BANK OVERDRAFTS. X 15000 15000 0 1 1 PETER DIAS OFFICER TO PROVIDE A FINANCIAL BUFFER FOR ORGANIZATION TO PREVENT BANK OVERDRAFTS. X 15000 15000 0 1 1 30000 FORM 990, PART VI, SECTION B, LINE 11B FORM 990 WAS REVIEWED BY THE PRESIDENT, THE CFO AND THE BOARD OF DIRECTORS PRIOR TO FILING. FORM 990, PART VI, SECTION B, LINE 12C A) THE CONFLICT OF INTEREST POLICY APPLIES TO ANY TRANSACTIONS OR ARRANGEMENTS THAT MIGHT BENEFIT THE PRIVATE INTEREST OF AN OFFICER DIRECTOR OR KEY EMPLOYEE OF BRISC OR ANY OTHER 'DISQUALIFIED PERSON' AS DEFINED IN SECTION 4958 (F)(1) OF THE INTERNAL REVENUE CODE AND WHICH MIGHT RESULT IN A POSSIBLE "EXCESS BENEFIT" TRANSACTION" AS DEFINED IN SECTION 4958 (C)(1)(A) OF THE INTERNAL REVENUE CODE AND AS AMPLIFIED BY SECTION 53.4958. THE FINANCIAL INTEREST CAN BE DIRECT OR INDIRECT, THROUGH BUSINESS INVESTMENT OR FAMILY. B) THE INTERESTED PERSON HAS A DUTY TO DISCLOSE ANY POTENTIAL CONFLICTS OF INTEREST TO THE BOARD OF DIRECTORS. DISINTERESTED MEMBERS OF THE BOARD THEN DETERMINE WHETHER A CONFLICT OF INTEREST EXISTS. THE PERSON WITH THE FINANCIAL INTEREST IS ABSENT DURING THESE DISCUSSIONS. C) POTENTIAL CONFLICTS OF INTEREST ARE REVIEWED BY DISINTERESTED MEMBERS OF THE BOARD OF DIRECTORS. AFTER EXERCISING DUE DILIGENCE, THE BOARD DETERMINES WHETHER A MORE ADVATANGEOUS ARRANGEMENT COULD BE MADE UNDER CIRCUMSTANCES NOT PRODUCING A CONFLICT OF INTEREST, WHETHER THE TRANACTION IS FAIR AND REASONABLE AND WHETHER IT IS IN THE CORPORATIONS BEST INTEREST TO PROCEED WITH THE TRANSACTION. A DECISION IS MADE BY MAJORITY VOTE. IF THE TRANSACTION PROCEEDS, IT IS REVIEWED PERIODICALLY BY THE BOARD TO DETERMINE WHETHER IT IS STILL IN THE CORPORATION'S BEST INTEREST. D) IF THE BOARD HAS CAUSE TO BELIEVE THAT AN OFFICER OR OTHER DISQUALIFIED PERSON FAILED TO DISCLOSE ACTUAL OR POSSIBLE CONFLICTS OF INTERST, IT SHALL INFORM THE PERSON OF THE BASIS OF THIS BELIEF AND ALLOW THEM TO EXPLAIN THE ALLEGED FAILURE TO DISCLOSE. IF AFTER HEARING THE RESPONSE AND INVESTIGATING THE MATTER, THE BOARD DETERMINES THERE IS A CONFLICT OF INTEREST, THE BOARD SHALL TAKE APPROPRIATE DISCIPLINARY AND CORRECTIVE ACTION. FORM 990, PART VI, SECTION B, LINE 15 DISINTERESTED MEMBERS OF THE BOARD OF DIRECTORS REVIEWED AND APPROVED THE PRESIDENT'S, CHIEF FINANCIAL OFFICER'S, OFFICER'S, AND KEY EMPLOYEE'S SALARIES. THE PROCESS INCLUDED A REVIEW OF SALARIES FOR THE SAME POSITIONS IN SIMILAR ORGANIZATIONS IN SAN DIEGO COUNTY (AS REPORTED ON THE ORGANIZATIONS' FORM 990S) AND DISCUSSION OF THE SALARIES. THE PRESIDENT, CFO, OFFICERS, AND KEY EMPLOYEES WERE NOT PRESENT DURING THESE DISCUSSIONS. A SUMMARY OF THE DISCUSSION AND SALARY REVIEW IS INCLUDED IN THE MINUTES OF THE BOARD OF DIRECTORS MEETING. FORM 990, PART VI, SECTION C, LINE 18 COPIES OF THESE DOCUMENTS WILL BE PROVIDED UPON REQUEST TO INTERESTED MEMBERS OF THE PUBLIC. FORM 990, PART VI, SECTION C, LINE 19 COPIES OF THESE DOCUMENTS WILL BE PROVIDED UPON REQUEST TO INTERESTED MEMBERS OF THE PUBLIC.